Last Updated: November 9, 2026

Details for Patent: 8,178,693

« Back to Dashboard


Summary for Patent: 8,178,693
Title:N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract:Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Inventor(s):Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
Assignee: Alexion Pharma International Operations Ltd , Array Biopharma Inc
Application Number:US12/824,559
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,178,693
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,178,693

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca KOSELUGO selumetinib sulfate CAPSULE;ORAL 213756-001 Apr 10, 2020 RX Yes No 8,178,693 ⤷  Start Trial Y Y ⤷  Start Trial
Astrazeneca KOSELUGO selumetinib sulfate CAPSULE;ORAL 213756-002 Apr 10, 2020 RX Yes Yes 8,178,693 ⤷  Start Trial Y Y ⤷  Start Trial
Astrazeneca KOSELUGO selumetinib sulfate GRANULE;ORAL 219943-001 Sep 10, 2025 RX Yes Yes 8,178,693 ⤷  Start Trial Y Y ⤷  Start Trial
Astrazeneca KOSELUGO selumetinib sulfate GRANULE;ORAL 219943-002 Sep 10, 2025 RX Yes No 8,178,693 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,178,693

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1482932 ⤷  Start Trial PA2019007 Lithuania ⤷  Start Trial
European Patent Office 1482932 ⤷  Start Trial LUC00100 Luxembourg ⤷  Start Trial
European Patent Office 1482932 ⤷  Start Trial 300974 Netherlands ⤷  Start Trial
European Patent Office 1482932 ⤷  Start Trial 2019C/510 Belgium ⤷  Start Trial
European Patent Office 1482932 ⤷  Start Trial CA 2019 00011 Denmark ⤷  Start Trial
European Patent Office 1482932 ⤷  Start Trial C20190010 00281 Estonia ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.